Evolent Health filings document the regulatory disclosures of a healthcare services company focused on complex specialty care and value-based care infrastructure. Its 8-K reports cover operating and financial results, material agreements, capital-structure matters, completed subsidiary transactions, and compensation arrangements tied to executive appointments.
Proxy materials disclose annual meeting matters, board oversight, director elections, executive compensation, and governance practices. Other current reports record board and officer transitions, equity incentives, and corporate events affecting Evolent Health, Inc. and its wholly owned subsidiary structure.
Evolent Health, Inc. reported first-quarter 2026 revenue of $496.2 million, slightly above $483.6 million a year earlier, reflecting growth across Medicaid, Medicare and commercial lines. The company recorded an operating loss of $10.6 million and a net loss of $26.6 million, a marked improvement from a $72.3 million loss a year ago, with loss per share narrowing to $0.24 from $0.63. Cash and restricted cash totaled $168.7 million, while long-term debt stood at $973.5 million, plus substantial term loans and revolving borrowings under its credit facilities. Management states current liquidity, including $142.0 million of unrestricted cash, is sufficient to cover at least the next twelve months. Reserves for claims and performance-based arrangements rose to $232.0 million, highlighting the scale of risk-sharing contracts in its value-based care model.
Evolent Health, Inc. reported first quarter 2026 revenue of $496.2 million, slightly above $483.6 million a year ago, as demand for its complex specialty care solutions remained strong. Net loss attributable to common shareholders narrowed to $26.6 million from $72.3 million, with loss per share improving to $(0.24) from $(0.63).
Profitability metrics weakened on an adjusted basis. Adjusted EBITDA declined to $22.1 million from $36.9 million and adjusted income swung to a $2.3 million loss from $7.4 million of income, reflecting higher medical costs. The medical expense ratio rose to 93.3%, indicating a larger share of revenue flowing to medical claims.
The company highlighted two new revenue agreements, including an imaging contract covering about 4.5 million lives and a Performance Suite expansion expected to generate over $200 million in annual revenue starting in the third quarter, subject to regulatory approvals. Evolent reiterated full-year 2026 guidance for revenue of $2.4–$2.6 billion and adjusted EBITDA of $110–$140 million. Cash and cash equivalents were $142.0 million as of March 31, 2026.
Evolent Health, Inc. has issued its 2026 proxy statement for a fully virtual annual meeting on June 4, 2026. Stockholders will vote on electing ten directors, ratifying Deloitte & Touche LLP as auditor, approving 2025 executive pay on an advisory basis, and amending the 2015 Omnibus Incentive Plan to increase shares available for future awards.
For 2025, Evolent reports revenue of $1,876.2 million, average unique members of 40.4 million, and Adjusted EBITDA of $151.2 million, while noting a stock price decline amid industry headwinds and policy changes. The company highlights strong new business wins, a refinancing of 2025 convertible notes that pushes the next major debt maturity to December 2029, and the sale of Evolent Care Partners to reduce senior debt and interest expense.
Governance updates include an Independent Board Chair, ongoing board refresh with three new independent directors in 2025, and fully independent key committees. The executive compensation program emphasizes pay-for-performance, mixes short- and long-term incentives, and uses PSUs tied to relative total shareholder return, with negative discretion applied to 2025 incentives to reflect share price performance.
Evolent Health Inc: The Vanguard Group filed an Amendment No. 8 to a Schedule 13G/A reporting that, following an internal realignment, certain Vanguard subsidiaries will report disaggregated holdings and that Vanguard's reported beneficial ownership of Evolent Health common stock is 0 shares (0%) as reflected in the filing dated 03/13/2026 and signed 03/26/2026.
Evolent Health, Inc. CEO Seth Blackley reported equity award activity and related tax-withholding transactions. He received a grant of 1,425,310 performance-based share units at a price of $0.00 per unit and acquired 58,921 shares of Class A Common Stock upon settlement of earlier performance-based units.
To cover tax obligations tied to these vesting and settlement events, a total of 24,053, 17,736, and 9,537 shares of Class A Common Stock were withheld at per-share prices of $3.51, $3.58, and $3.25, respectively. After these transactions, Blackley directly owned 836,962 shares of Class A Common Stock and 1,425,310 performance-based share units, with the new PSUs eligible to be earned from March 1, 2027 to February 28, 2029 based on stock price and service conditions.
Evolent Health, Inc. General Counsel Jonathan Weinberg reported several equity compensation transactions involving the company’s Class A Common Stock and performance-based share units. On March 2, 2026, he received a grant of 179,661 performance-based share units at no cash cost and a separate award of 4,910 shares of Class A Common Stock.
On the same date, 1,896 shares were withheld at prices of $3.58 per share to cover tax obligations, and on March 1, 2026, an additional 4,406 shares were withheld at $3.25 per share for tax withholding. On March 3, 2026, a further 8,275 shares were withheld at $3.51 per share for tax liabilities. These “F” coded transactions reflect tax-withholding dispositions, not open-market sales, and left Weinberg with 244,512 shares of Class A Common Stock held directly.
Footnotes explain that some shares were delivered upon settlement of earlier performance-based awards after achievement of specified performance metrics, and the new PSUs may be earned between March 1, 2027 and February 28, 2029 based on stock price and service conditions, with potential payout from 0% to 250% of target.
Evolent Health president Daniel McCarthy reported a mix of equity grants and tax-related share withholdings. He received 826,440 performance-based share units at target under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan, which may be earned based on specified stock price performance conditions from March 1, 2027 to February 28, 2029, subject to service conditions.
McCarthy also acquired 39,281 shares of Class A common stock upon settlement of a prior performance-based share unit award that vested at the end of 2025 after performance certification on March 2, 2026. To satisfy tax withholding obligations on vested restricted stock units and settled PSUs, 24,027, 18,192 and 7,811 Class A shares were withheld at prices between $3.25 and $3.58 per share. Following these transactions, he directly owned 423,022 Class A shares.
Evolent Health Chief Accounting Officer Shams Aammaad reported equity compensation activity and related tax withholding transactions. He received a grant of 55,173 performance-based share units (PSUs) and 1,686 shares of Class A Common Stock as awards. In separate moves, a total of 4,311, 850 and 2,577 Class A shares were withheld to cover tax obligations upon vesting and settlement of prior awards, described as tax-withholding dispositions rather than open-market sales. The new PSUs can be earned based on stock price performance conditions measured from March 1, 2027 to February 28, 2029, with potential payout from 0% to 250% of the target level, subject to service-based conditions.
Ramos Mario reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. Chief Financial Officer Mario Ramos received a grant of 429,041 performance-based share units (PSUs) at a price of $0.00 per unit. The PSUs are granted under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan and may be earned based on stock price performance between March 1, 2027 and February 28, 2029, subject to service-based conditions. Each PSU is currently shown at a target level, and the final number earned can range from 0% to 250% of this target after the performance period.